CE InformationDownload MaterialsCourse Progress
  • Access Webinar
  • Evaluation
  • Certificate
Evaluation

Addressing Unmet Needs in Ulcerative Colitis: Understanding the Utility of Newer and Emerging Targeted Therapies

Evaluation

HMP Education would appreciate your feedback on the quality and impact of this activity.

Please answer the following questions, some of which include a 5-point Likert scale (5 = strongly agree/excellent/great deal; 1 = strongly disagree/poor/very little).

To what extent are you able to better achieve each of the following learning objectives?

Describe the prevalence, burden, and pathophysiology of UC and associated risk factors for disease development and progression
Evaluate the mechanisms of action and clinical data associated with newer and emerging drug classes, including S1PR modulators and JAK inhibitors, and their role in the UC treatment paradigm
Outline strategies for optimizing UC management and addressing treatment challenges in clinical practice

Please rate the faculty on their knowledge, expertise, and teaching ability (5= excellent, 3 = good, 1 = poor).

Millie D. Long, MD, MPH, FACG
Corey A. Siegel, MD, MS
Remo Panaccione, MD

Please rate the following components relating to this activity:

Content
Relevance to your practice 
Educational format 
Audience-participation portions (eg., Q&A, polling, pre/post-testing) 
Resources and/or other materials supporting the activity
Overall

Therapeutic recommendations presented in this activity did not encourage inappropriate or excessive use of products/devices.
How many patients do you encounter with UC on a weekly basis?

Do you feel like there were any new data presented?

Did you learn anything new?

Did you gain confidence on the new information?

Did this program include opportunities to learn as a part of a healthcare team?
According to ACG guidelines, mild UC can be defined by which of the following?
Which of the following best describes the mechanism of action of S1P receptor modulators to address the chronic inflammation associated with the pathogenesis of IBD?
Which of the following is a selective S1P receptor modulator (engaging S1P receptors 1, 4, and 5) that demonstrated statistically significant improvements in clinical remission, endoscopic improvement, symptomatic remission, and mucosal healing among patients with moderate to severe UC at weeks 12 and 52?
How confident are you now in your ability to optimally position S1P receptor modulators and JAK inhibitors in tailored UC treatment plans?

Do you intend to make any additional changes to your practice as a result of information gained from this activity? Please be specific.
What challenges or barriers outside of your control may prevent you from changing your practice?
255 characters max

The information presented in this activity did not serve to advance a proprietary interest of any commercial entity.
Based on my participation in this activity, I anticipate I will more often (select all that apply):